Investmentaktiengesellschaft Fuer Langfristige Investoren TGV Boosts Stake in BioNTech SE (NASDAQ:BNTX)

Investmentaktiengesellschaft Fuer Langfristige Investoren TGV increased its position in BioNTech SE (NASDAQ:BNTX) by 41.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 20,500 shares of the company’s stock after purchasing an additional 6,000 shares during the period. BioNTech accounts for about 0.1% of Investmentaktiengesellschaft Fuer Langfristige Investoren TGV’s holdings, making the stock its 17th biggest holding. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV’s holdings in BioNTech were worth $1,647,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Neuberger Berman Group LLC purchased a new stake in shares of BioNTech in the 4th quarter valued at about $1,562,000. Truist Financial Corp acquired a new position in BioNTech in the 4th quarter valued at about $1,445,000. US Bancorp DE increased its position in BioNTech by 420.7% in the 4th quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after acquiring an additional 23,119 shares during the period. Goldman Sachs Group Inc. increased its position in BioNTech by 17.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after acquiring an additional 26,777 shares during the period. Finally, Harding Loevner LP acquired a new position in BioNTech in the 4th quarter valued at about $410,984,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several recent research reports. Evercore ISI initiated coverage on BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target on the stock. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. TD Cowen dropped their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. JPMorgan Chase & Co. dropped their target price on BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research report on Thursday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Tuesday, August 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.09.

BioNTech Price Performance

Shares of NASDAQ BNTX traded up $0.62 on Friday, hitting $88.22. The company’s stock had a trading volume of 595,112 shares, compared to its average volume of 728,051. The stock has a 50 day moving average of $84.02 and a 200-day moving average of $89.33. The company has a market capitalization of $20.98 billion, a price-to-earnings ratio of 176.44 and a beta of 0.23. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $125.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same quarter last year, the company posted ($0.86) EPS. BioNTech’s quarterly revenue was down 23.3% compared to the same quarter last year. As a group, research analysts predict that BioNTech SE will post -2.8 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.